Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking

Journal of Clinical Psychopharmacology

Volumn 13, Issue 6, 1993, Pages 383-390

  Hasegawa, Mitsuru ^a   Gutierrez Esteinou, Rolando ^a   Way, Lynne ^a   Meltzer, Herbert Y ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DRUG METABOLITE; NORCLOZAPINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SMOKING;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; FEMALE; HUMAN; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027740188     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.
2. Meltzer HY, Bastani B, Ramirez LF, Matsubara S: Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989;238:332–9.
3. Meltzer HY, Luchins DJ: Effect of clozapine in severe tardive dvskinesia: a case report. J Clin Psychopharmacol 1984;4:286–7.
4. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J: The effect of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503–10.
5. Krupp P, Barnes P: Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berlin) 1989:99(suppl):S118–21.
6. Meltzer HY, Kane J, Kolakowska T: Plasma levels of neuroleptics, prolactin levels and clinical response. In: JT Coyle, SJ Enna, eds. Neuroleptics, neurochemical, behavioral and clinical perspectives. New York: Raven Press, 1983:255–79.
7. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma levels in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79–91.
8. Van Putten T, Marder S, Wirshing WC, Aravagiri M, Chabert N: Neuroleptic plasma levels. Schizophr Bull 1991;17:197–216.
9. Thorup M, Fog R: Clozapine treatment of schizophrenic patients: plasma concentration and coagulation factors. Acta Psychiatr Scand 1977;55:123–6.
10. Ackenheil M, Bräu H, Burkhart A, Franke A, Pacha W: Antipsy-chotische wirksamkeit im verhältnis zum plasmaspiegel von Clozapin. Arzneimittelforschung 1976;26:1156–8.
11. Bräu VH, Burkhart A, Pacha W, Ackenheil M: Benziehungen zwischen Wirkungen und Plasmaspiegel von Clozapin. Arzneimittelforschung 1978;1300–1.
12. Perry PJ, Miller DD, Arndt SV, Cadoret RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231–5.
13. Owen JA, Delva JN, Lawson JS: Clozapine concentrations and clinical response in schizophrenic patients. Am J Psychiatry 1992;149:1120–1.
14. Haring C, Barnas C, Saria A, Humpel C, Fleischhacker WW: Dose-related plasma levels of clozapine. J Clin Psychopharmacol 1989;9:71–2.
15. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A: Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471–5.
16. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892–7.
17. 17. Endicott J, Spitzer RL: A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837–44.
18. Overall JE, Gorham DR: Brief psychiatric rating scale (BPRS). Psychol Rep 1962;10:799–812.
19. Lovdahl MJ, Perry PJ, Miller DD: The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit 1991;13:69–72.
20. Bondesson V, Lindström LH: Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berlin) 1988;95:472–5.
21. Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: an atypical antipsychotic agent. Clin Pharmacy 1989;8:691–709.
22. Arndt SV: Response to Owen et al. Am J Psychiatry 1992;149:1121.
23. Stimmel GL, Falloon IRH: Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983;44:420–2.
24. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrinton CA, Davis CA: Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berlin) 1986;90:468–70.
25. Ereshefsky L, Jann MW, Saklad ST, Davis CM, Richards AL, Burch NR: Effects of smoking on fluphenazine clearance in psychotic inpatients. Biol Psychiatry 1985;20:329–32.
26. Jusko WJ: Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:7–39.
27. Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J: Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988;34:445–9.
28. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R: Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990;7:347–51.
29. Ackenheil M: Clozapine—pharmacokinetic investigators and biochemical effects in man. Psychopharmacology (Berlin) 1989;99:532–7.
30. Miller DD: Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23–5.
31. Szymanski S, Jeffrey DO, Liberman A, Picou D, Masiar S, Cooper T: A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21–2.
32. Simpson GM, Cooper TA: Clozapine plasma levels and convulsions. Am J Psychiatry 1978;135:99–100.